MiMedx Group (MDXG) Q3 2024 earnings summary

Executive summary

• Net sales grew 3% year-over-year to $84 million in Q3 2024, driven by AMNIOEFFECT, EPIEFFECT, and initial HELIOGEN sales, partially offset by sales team turnover and discontinued dental and AXIOFILL products.

• GAAP net income from continuing operations was $8 million with a net income margin of 9.4% for Q3 2024; adjusted EBITDA was $18 million, representing a 22% margin.

• Cash and cash equivalents increased by $20 million in the quarter, reaching $89 million, aided by debt refinancing and improved interest income.

• Product innovation, including the limited market release of HelioGen, and strong international growth offset reimbursement headwinds and market disruption.

• Showcased product portfolio at SAWC Fall and featured in The New York Times for placental allografts.

Financial highlights

• Q3 2024 net sales: $84 million (+3% YoY); gross profit: $69 million, gross margin at 81.8%.

• Adjusted EBITDA: $18 million, 22% of net sales, flat year-over-year.

• Adjusted net income: $10.4 million ($0.07/share), up from $8 million ($0.05/share) last year.

• Free cash flow for the nine months ended September 30, 2024, was $45.9 million, up from $14.9 million in the prior year period.

• Cash and cash equivalents stood at $89 million as of September 30, 2024; no borrowings outstanding and $75 million available under Revolving Credit Facility.

Outlook and guidance

• Raised full-year 2024 net sales growth guidance to the high end of the prior mid- to high single-digit range; full-year adjusted EBITDA margin projected above 20%.

• Longer-term, annual net sales growth is targeted in the low double-digits with strong margin profile.

• Management expects to meet operational liquidity needs for the next twelve months with current cash, operating activities, and available credit.

• SG&A expected to remain stable near current levels in the near term; R&D spend may increase slightly due to ongoing clinical studies.